Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Research question finder
Find source-linked psilocybin evidence for a research question, explore matching publications and trial records, and keep findings separate from registration.
Free access · No subscription for research tools or data exports
Start with a question, then inspect the evidence
This finder connects questions to curated evidence and matching bibliographic records. It does not generate clinical advice or claim that a keyword match answers the question.
Selected evidence relevant to this question
These are original educational annotations from the evidence guide, not a new systematic review. Follow each original report and inspect its population, comparator, endpoint and safety findings.
Swiss relapse-prevention trial · 2025
Primary comparisons inconclusiveNeither primary comparison was significant: abstinence p=0.55; alcohol use p=0.51. Six-month comparisons also showed no significant group difference.
Small sample; a different population, dosing schedule and psychotherapy programme from the 2022 trial. The result does not establish equivalence or rule out a clinically relevant effect.
Source checked 2026-10-07Bogenschutz et al. · 2022
Primary endpoint favored psilocybin9.7% with psilocybin versus 23.6% with active placebo: 13.9 percentage points fewer heavy drinking days (95% CI 3.0–24.7), p=0.01.
Participants could often identify their allocation. Results concern the combined supervised intervention and selected participants, not psilocybin alone or every person with alcohol use disorder.
Source checked 2026-10-07Bogenschutz et al. · 2015 pilot
Preliminary uncontrolled findingThe investigators observed increased abstinence after dosing, with gains broadly maintained through 36 weeks.
Without a concurrent control, improvement cannot be attributed specifically to psilocybin. This preliminary report supported further trials rather than confirming efficacy.
Source checked 2026-10-07Matching indexed literature
356 records match alcohol. First 20 shown; status and source labels describe records, not an independent review of their findings.
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease2026-10-08 · ClinicalTrials.gov · CLINICAL TRIALPsilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression.2026-10-06 · PubMed · PublishedReduced egocentricity after psilocybin in patients with alcohol use disorder: a pilot randomized controlled trial2026-09-29 · medRxiv · PREPRINT (not peer reviewed)Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial2026-09-24 · ClinicalTrials.gov · CLINICAL TRIALImplications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.2026-09-13 · Europe PMC · PublishedNeurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder2026-09-02 · ClinicalTrials.gov · CLINICAL TRIALAge and Cannabis Co-Use Are Associated with Differences in Experience and Perceived Benefits of Psilocybin: A Retrospective Study.2026-09-02 · Europe PMC · PublishedPatterns of Psychedelic Use in Italy: Insights from the Global Psychedelic Survey2026-09-01 · OpenAlex · PublishedA Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.2026-09-01 · PubMed · PublishedMedical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases2026-08-26 · Europe PMC · PREPRINT (not peer reviewed)Adverse Effect-Related Language in Recreational Psychedelic and non-Psychedelic Substance Experience Reports.2026-08-22 · Europe PMC · PublishedSafety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services2026-08-19 · Crossref · PublishedPsilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworks.2026-08-17 · Europe PMC · PublishedPsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)2026-08-13 · ClinicalTrials.gov · CLINICAL TRIALPsilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanisms2026-08-01 · Crossref · PublishedMystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.2026-08-01 · PubMed · PublishedA Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin2026-07-17 · ClinicalTrials.gov · CLINICAL TRIALNational bill seeks to jump-start psychedelic treatment for veterans2026-07-11 · OpenAlex · PublishedComputationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects2026-07-09 · ClinicalTrials.gov · CLINICAL TRIALPast-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms2026-07-01 · Crossref · Published
Search, refine and export these records